Polio Resurfaces in Laos

Genetic sequencing of the virus suggests it has been circulating for two years in an area with low immunization rates

Join Our Community of Science Lovers!

By Reuters Staff

GENEVA/LONDON (Reuters) - Laos has suffered a case of vaccine-derived polio, the World Health Organization said on Monday, in a new setback to a global plan to eradicate the crippling disease after the virus resurfaced in Ukraine and Mali.

The WHO said an 8-year-old boy died of the disease on Sept. 11, and genetic sequencing suggested the virus strain has been circulating in the area of Bolikhamxay province, which has low immunization rates, for more than two years.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

A global vaccination campaign has all but beaten the wild polio virus, with only Pakistan and Afghanistan reporting cases of wild polio virus infection this year.

Specialists have warned that vaccine-derived cases - such as this one in Laos and previous ones in Ukraine and Mali - could hamper progress towards global eradication.

The WHO stressed that "ending polio for good requires eliminating both wild and vaccine-derived polio".

It added, however, that because of relatively limited travel to and from this area, and because of extra immunization campaigns planned in response, the risk of international spread of this polio strain from Laos is low.

Laos has been free of the wild polio virus since 1993, but poor immunization rates mean people are at risk of infection with strains of the virus that can mutate in sewage after being excreted by immunized children.

The risk of vaccine-derived polio cases can be avoided by switching from using live oral polio vaccines (OPV) - which are highly effective, cheap, easy to deliver but contain live virus, - to "inactivated" vaccines (IPV), which are not effective for fighting endemic disease but contain no live virus.

The WHO said the use of OPV is being scaled down in a phased manner as countries eliminate circulating wild polio virus strains.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American